MX373466B - Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion. - Google Patents

Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion.

Info

Publication number
MX373466B
MX373466B MX2016003871A MX2016003871A MX373466B MX 373466 B MX373466 B MX 373466B MX 2016003871 A MX2016003871 A MX 2016003871A MX 2016003871 A MX2016003871 A MX 2016003871A MX 373466 B MX373466 B MX 373466B
Authority
MX
Mexico
Prior art keywords
compositions
proteins
coagulation factor
human recombinant
heterogeneous populations
Prior art date
Application number
MX2016003871A
Other languages
English (en)
Spanish (es)
Other versions
MX2016003871A (es
Inventor
Jason C Rouse
Keith A Johnson
Mary Beth Switzer
Michael Anthony Jankowski
Michael Shamashkin
Penelope Jane Sharpe
Stacey B Weston
Wendy Carol Piacenza
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2016003871A publication Critical patent/MX2016003871A/es
Publication of MX373466B publication Critical patent/MX373466B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6432—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Water Supply & Treatment (AREA)
  • Toxicology (AREA)
MX2016003871A 2013-09-24 2014-09-16 Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion. MX373466B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361881834P 2013-09-24 2013-09-24
PCT/IB2014/064564 WO2015044836A1 (en) 2013-09-24 2014-09-16 Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins

Publications (2)

Publication Number Publication Date
MX2016003871A MX2016003871A (es) 2016-08-04
MX373466B true MX373466B (es) 2020-05-25

Family

ID=51844797

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016003871A MX373466B (es) 2013-09-24 2014-09-16 Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion.

Country Status (19)

Country Link
US (3) US9757434B2 (enExample)
EP (1) EP3049434A1 (enExample)
JP (1) JP6429885B2 (enExample)
KR (1) KR101988705B1 (enExample)
CN (2) CN112195169A (enExample)
AR (1) AR097732A1 (enExample)
AU (1) AU2014326257B2 (enExample)
BR (1) BR112016005899A8 (enExample)
CA (1) CA2924981C (enExample)
HK (1) HK1218760A1 (enExample)
IL (2) IL244258A0 (enExample)
MX (1) MX373466B (enExample)
MY (1) MY173548A (enExample)
PE (1) PE20160877A1 (enExample)
RU (1) RU2648144C2 (enExample)
SA (1) SA516370751B1 (enExample)
SG (1) SG11201601221XA (enExample)
TW (1) TWI631134B (enExample)
WO (1) WO2015044836A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1215196A1 (zh) 2013-01-31 2016-08-19 辉瑞公司 用於抵消因子xa抑制的组合物和方法
CN112195169A (zh) 2013-09-24 2021-01-08 辉瑞大药厂 包含重组人凝血因子Xa蛋白的异质性群体的组合物
EP3926044B1 (en) 2016-06-17 2025-06-04 Alexion Pharmaceuticals, Inc. Preparation of factor xa derivatives
EP3722418A1 (en) * 2019-04-08 2020-10-14 AB Enzymes Oy Solution stable enzyme composition
EP4127158A2 (en) * 2020-04-02 2023-02-08 Takeda Pharmaceutical Company Limited Adamts13 variant, compositions, and uses thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597799A (en) 1990-09-04 1997-01-28 Cor Therapeutics, Inc. Recombinant agents affecting thrombosis
AT405517B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-deletionsmutanten und analoge davon
AT405516B (de) 1997-02-27 1999-09-27 Immuno Ag Faktor x-analoge mit modifizierter proteasespaltstelle
AT410216B (de) 1999-08-10 2003-03-25 Baxter Ag Faktor x-analogon mit verbesserter aktivierbarkeit
AU2001249389A1 (en) 2000-03-22 2001-10-03 The Children's Hospital Of Philadelphia Modified blood clotting factors and methods of use
FR2831170B1 (fr) 2001-10-19 2004-03-19 Inst Nat Sante Rech Med Proteines c modifiees activables directement par la thrombine
FR2841904B1 (fr) 2002-07-03 2004-08-20 Inst Nat Sante Rech Med Analogues de facteurs x clivables par la thrombine
RU2396347C2 (ru) * 2004-08-17 2010-08-10 Ксл Бехринг Гмбх Модифицированные витамин к-зависимые полипептиды
EP1728798A1 (en) 2005-06-01 2006-12-06 ZLB Behring GmbH Coagulation factor X polypeptides with modified activation properties
MX336958B (es) * 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
EP1820508A1 (en) 2006-02-21 2007-08-22 CSL Behring GmbH Coagulation factor X polypeptides with modified activation properties
KR102069498B1 (ko) * 2007-09-28 2020-01-23 포톨라 파마슈티컬스, 인코포레이티드 인자 Xa 저해제에 대한 안티도트 및 그것을 사용하는 방법
US8329871B2 (en) 2008-06-24 2012-12-11 Octapharma Ag Process of purifying coagulation factor VIII
CA2743496C (en) * 2008-11-14 2018-03-27 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same in combination with blood coagulating agents
JP5833448B2 (ja) 2008-12-19 2015-12-16 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル セリンプロテアーゼ誘導体および血液凝固疾患の予防または処置における使用
EP2453910B1 (en) 2009-07-15 2016-08-31 Portola Pharmaceuticals, Inc. Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding
PT2591006T (pt) * 2010-07-09 2019-07-29 Bioverativ Therapeutics Inc Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
FR2972114B1 (fr) 2011-03-01 2013-03-15 Univ Grenoble 1 Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur
JP6514893B2 (ja) 2011-09-30 2019-05-15 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia 止血を調節するための組成物および方法
KR102049900B1 (ko) 2012-07-25 2019-11-28 카탈리스트 바이오사이언시즈, 인코포레이티드 변형 인자 x 폴리펩티드 및 이의 용도
HK1215196A1 (zh) 2013-01-31 2016-08-19 辉瑞公司 用於抵消因子xa抑制的组合物和方法
CN112195169A (zh) 2013-09-24 2021-01-08 辉瑞大药厂 包含重组人凝血因子Xa蛋白的异质性群体的组合物
US20160235824A1 (en) 2013-11-01 2016-08-18 The Children's Hospital Philadelphia Compositions and Methods for Increasing the Half-Life of Factor XA
CN105934250A (zh) 2014-01-24 2016-09-07 辉瑞公司 治疗脑内出血的组合物和方法

Also Published As

Publication number Publication date
TW201524996A (zh) 2015-07-01
HK1218760A1 (zh) 2017-03-10
JP2016535071A (ja) 2016-11-10
US20210106658A1 (en) 2021-04-15
BR112016005899A2 (pt) 2017-09-26
RU2016108608A (ru) 2017-10-26
EP3049434A1 (en) 2016-08-03
SA516370751B1 (ar) 2018-04-05
US20170333535A1 (en) 2017-11-23
CA2924981C (en) 2020-03-31
KR101988705B1 (ko) 2019-06-12
CN112195169A (zh) 2021-01-08
RU2648144C2 (ru) 2018-03-22
CN105579468A (zh) 2016-05-11
PE20160877A1 (es) 2016-09-11
AR097732A1 (es) 2016-04-13
US10660946B2 (en) 2020-05-26
IL279396A (en) 2021-01-31
US20150182604A1 (en) 2015-07-02
IL244258A0 (en) 2016-04-21
AU2014326257B2 (en) 2017-08-10
MY173548A (en) 2020-02-04
SG11201601221XA (en) 2016-04-28
JP6429885B2 (ja) 2018-11-28
BR112016005899A8 (pt) 2018-02-06
MX2016003871A (es) 2016-08-04
CA2924981A1 (en) 2015-04-02
TWI631134B (zh) 2018-08-01
US9757434B2 (en) 2017-09-12
AU2014326257A1 (en) 2016-03-10
WO2015044836A1 (en) 2015-04-02
KR20160044034A (ko) 2016-04-22

Similar Documents

Publication Publication Date Title
CY1124436T1 (el) Δικυκλικες ετεροκυκλικες ενωσεις και χρησεις αυτων στη θεραπεια
CY1126072T1 (el) Περιοχες gla ως θεραπευτικοι παραγοντες
BR302013006822S1 (pt) Configuração aplicada em curativo médico.
IL255119B (en) Therapeutic pooled blood apoptotic cell preparations and uses thereof
EA201491856A1 (ru) Терапевтическое применение белков фактора роста фибробластов 21
MX2020000083A (es) Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand.
IL242137B (en) Methods and compositions for wound healing
EP2988771A4 (en) FIBRINOGENIC FABRIC PADS
EP2889308A4 (en) CONEPOXIN PEPTIDE OF THE ALPHA O-SUPERFAMILY, PHARMACEUTICAL COMPOSITION AND USE THEREOF
IL279396A (en) Preparations containing heterogeneous populations of recombinant human coagulation factor XA proteins
EP2974751A4 (en) HEART OR TISSUE SPHERE
UA117933C2 (uk) Поліпептид, здатний зв'язувати с5-компонент комплементу людини
EA201390955A1 (ru) Слитый белок robo1-fc для применения в лечении гепатокарциномы
EP3359962A4 (en) BLOOD PREPARATION AND PROFILING
MX387579B (es) Polipéptidos del factor vii de acción corta.
MX2016004702A (es) Polipeptidos del factor vii de coagulacion.
PL2904009T3 (pl) Związki do leczenia blokady mielinizacji w chorobach związanych z ekspresją białka otoczki herv-w
EP3752113C0 (en) SURGICAL GAUZE
EA201692161A1 (ru) Прогемостатические белки для лечения кровотечений
WO2013109190A3 (en) Cho-gmt recombinant protein expression
BR112014018709A8 (pt) Composições e efetores de beta-arrestina e métodos de uso dos mesmos
PH12016500509A1 (en) Compositions comprising heterogeneous populations of recombinant human clotting factor xa proteins
MX2015007625A (es) Composiciones sellantes.
MX385558B (es) Péptidos y métodos de uso.
TH1501000355A (th) วิธีผลิตสารองค์ประกอบเพปไทด์คอลลาเจน สารกด dpp-4 และสารยับยั้งการเพิ่มสูงขึ้นของค่าน้ำตาลในเลือด

Legal Events

Date Code Title Description
FG Grant or registration